NeurologyLive® Friday 5 — April 4, 2025

Author(s):

Key Takeaways

Advanced imaging techniques like OCT are crucial in diagnosing and managing multiple sclerosis, with ongoing research needed for clinical optimization.
The Phase 3 APOLLOE4 study investigates valiltramiprosate's efficacy in Alzheimer's patients with APOE4/4, offering new therapeutic insights.
Genetic research in oculopharyngeal muscular dystrophy highlights challenges in diagnosis and treatment, emphasizing the need for further advancements.
Targeting complement may mitigate amyloid-related imaging abnormalities, offering therapeutic potential in antiamyloid therapies.
Multimodal approaches to neural regeneration, including pharmacological and noninvasive strategies, are being explored for neural repair.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 4, 2025.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Bridging Neurology and Ophthalmology in Multiple Sclerosis Research

In this episode, neurologists discuss the role of advanced imaging, like OCT, in diagnosing and managing MS, emphasizing the need for further research to optimize its clinical application. [WATCH TIME: 2 minutes]

2: Overviewing Design and Topline Data From Phase 3 APOLLOE4 Study of Valiltramiprosate in Alzheimer Disease: Anton Porsteinsson, MD

The director of the Alzheimer’s Disease Care, Research, and Education Program at the University of Rochester provided clinical insight on a pivotal trial testing a novel therapeutic in patients with Alzheimer disease who are carriers of APOE4/4. [WATCH TIME: 7 minutes]

3: Insights into OPMD and Advancements in Genetic Research: Matthew Wicklund, MD

The professor of neurology at the University of Texas Health Science Center San Antonio provided clinical insights on the genetic basis of oculopharyngeal muscular dystrophy, as well as the primary challenges in diagnosing and treating the condition. [WATCH TIME: 5 minutes]

4: NeuroVoices: Cynthia Lemere, PhD, on Exploring the Role of Complement in ARIA and CAA

The professor of neurology at Brigham and Women’s Hospital gave clinical insights on the therapeutic potential of targeting compliment as a way to mitigate risk for amyloid-related imaging abnormalities from antiamyloid therapies.

5: Exploring Multimodal Approaches to Neural Regeneration: Kuldip Dave, PhD

The senior vice president of research at The ALS Association talked about a multidisciplinary session presented at the 2025 MDA Conference that highlighted diverse strategies for neural repair, from pharmacological targets to noninvasive brain stimulation. [WATCH TIME: 6 minutes]